The Blue Box Biomedical Solutions Secures €3Million Funding

The company is developing an AI-powered, urine-based breast cancer screening test that’s non-invasive, radiation-free, and pain-free—designed for use in gynecology clinics.

Breast cancer is the most treatable cancer but still the leading cause of cancer death in women, partly because current screenings miss up to 1 in 3 cases. The issue is worse for women with dense breast tissue, where mammograms are less effective.

The Blue Box (TBB) detects breast cancer by identifying a unique pattern of volatile organic compounds (VOCs) in urine, not just a single biomarker. A chemical sensor collects the VOCs, and an AI algorithm analyzes them to spot early signs of cancer.

Read Also - Norway Based Two Secures €13M Funding To Scale Its B2B Payments Solutions

This scalable, pattern-based test can improve early detection for women who avoid or lack access to traditional screening. It’s shown better sensitivity than mammography, helping catch more cancers earlier.

Unconventional Ventures led the funding round, joined by Fund F, Grow Ventures, and impact-driven investors like Hans(wo)man Group and Foss/Krups Family. The Spanish Association Against Cancer also backed the round, validating both the science and the need.

Long-time mentors and repeat investors, including Robert Masse, femtech investor Torsten Kolind (who is also on the board), and Matt Cooper, also participated.

“This milestone allows us to move full speed ahead with our European clinical trials and regulatory roadmap,” said Judit Giró, CEO and co-founder of The Blue Box.

“It also marks an important validation of the years of scientific and technical work behind our solution. Breast cancer is still detected too late for too many women around the world.

We are committed to changing that by offering a test that is not only accurate and affordable but also simple enough to be used anywhere. With this funding, we are taking a decisive step toward making non-invasive early detection a new standard of care.”

According to Thea Messel, General Partner at Unconventional Ventures, lead investor and director of The Blue Box’s board of directors, the Firm invested in The Blue Box because “we believe it represents a true paradigm shift in breast cancer detection.”

“We were convinced by the passion and vision of founders Judit Giró Benet and Lidia Navarro. Their relentless dedication to advancing women's health and their clear strategic roadmap for clinical trials and market entry inspire our utmost confidence.

We firmly believe in their ability to execute and scale this transformative technology, ultimately saving lives and improving women's health on a global scale and are proud to be partnering with them on this impactful mission.”

“We invested in The Blue Box because we are impressed by Judit’s & Lidia’s expertise and the team's commitment and believe their non-invasive, radiation-free breast cancer screening technology has the potential to transform early detection, significantly reducing barriers to access, ultimately improving patient outcomes globally.” shared Carina Roth, Investment Manager at Fund F.

With clinical trials set to begin soon the new funding will be used to manufacture medical-grade devices, recruit study participants, and prepare the technical documentation needed to meet CE certification standards.

About The Blue Box

Founded in 2021, The Blue Box is developing a urine-based breast cancer test with 88.42% sensitivity—15% better than mammography and 30% better for women with dense breasts. With clinical trials starting in 2025, the test aims to reach gynecology clinics by 2026, improving early detection and saving lives.